Sub menu

 
 

ZERBAXA (Merck Sharp & Dohme (Australia) Pty Ltd)

Product name
ZERBAXA
Sponsor
Merck Sharp & Dohme (Australia) Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
243 (255 working days)
Active ingredients
ceftolozane sulfate, tazobactam sodium
Registration type
EOI
Indication

ZERBAXA (ceftolozane/tazobactam) is indicated for the treatment of adult and paediatric (birth to less than 18 years of age) patients with the following infections caused by designated susceptible microorganisms:

  • - Complicated intra-abdominal infections in combination with metronidazole
  • - Complicated urinary tract infections, including pyelonephritis

    • Help us improve the Therapeutic Goods Administration site